MMW - Fortschritte der Medizin

, Volume 154, Issue 6, pp 70–73 | Cite as

So wird sie doch noch behandelbar

„Therapierefraktäre“ arterielle Hypertonie
SEMINAR FORTBILDUNG
  • 14 Downloads

Die therapierefraktäre Hypertonie ist eine Ausschlussdiagnose, wobei insbesondere Non-Compliance, Medikamenten-Interaktionen sowie sekundäre Hypertonie-Ursachen geprüft werden müssen. Therapeutisch ist eine Optimierung der medikamentösen Therapie angezeigt, ggf. auch die renale Denervierung oder die Barorezeptorstimulation.

Keywords

Resistant arterial hypertension Resistant hypertension interventional therapy of hypertension renal denervation baroreceptor stimulation 

Literaturverzeichnis

  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pres-sure: the JNC 7 report. JAMA 2003; 289: 2560–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Lowel H, Meisinger C, Heier M, Hymer H, Alte D, Volzke H: [Epidemiology of hyper-tension in Germany. Selected results of population-representative cross-sectional studies]. Dtsch Med Wochenschr 2006; 131: 2586–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: 510–26.CrossRefGoogle Scholar
  5. 5.
    Mancia G, De Backer G, Dominiczak A, et al: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiol-ogy (ESC). Eur Heart J 2007; 28: 1462–536.PubMedGoogle Scholar
  6. 6.
    Egan B, Zhao Y, Rehman, SU et al: Treatment resistant hypertension in a community-based practice network. J Clin Hypertens (Greenwich) 2009; 12: 6.Google Scholar
  7. 7.
    Muxfeldt ES, Nogueira Ada R, Salles GF, Bloch KV: Demographic and clinical charac-teristics of hypertensive patients in the internal medicine outpatient clinic of a university hospital in Rio de Janeiro. Sao Paulo Med J 2004; 122: 87–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF: True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18: 1534–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM: Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712–8.PubMedGoogle Scholar
  10. 9a.
    Václavík J, Sedlák R, Plachý M, Navrátil K. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial Hypertension 2011, 57:1069–1075Google Scholar
  11. 10.
    Heusser K, Tank J, Engeli S, et al.: Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619–26.PubMedCrossRefGoogle Scholar
  12. 11.
    Bisognano JD, Bakris, G, Nadim MK et al. Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension. J Am Coll Cardiol 2011;58:765–73.PubMedCrossRefGoogle Scholar
  13. 12.
    Krum H, Schlaich MP, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275–81.PubMedCrossRefGoogle Scholar
  14. 13.
    Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932–4.PubMedCrossRefGoogle Scholar
  15. 14.
    Symplicity HTN-2 Investigators: Renal sympathetic denervation in patients with treat-ment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet 2010;376:1903-9.Google Scholar
  16. 15.
    Schlaich MP, Krum H, Walton T, Whitbourn R, Sobotka P, Esler M: Two-Year Durability of Blood Pressure Reduction With Catheter-Based Renal Sympathetic Denervation. J Hypertens 2010; 28:446.CrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  1. 1.Stellv. Direktor, Med. Klinik IIUniversitätsklinikum Schleswig-HolsteinLübeckDeutschland

Personalised recommendations